Tags

Type your tag names separated by a space and hit enter

IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases.
Sci Rep. 2020 Jul 03; 10(1):11010.SR

Abstract

IgM antibodies against phosphorylcholine (anti-PC) and malondialdehyde (anti-MDA) may have protective properties in cardiovascular and rheumatic diseases. We here compare these antibodies in systemic rheumatic conditions and study their properties. Anti-PC and anti-MDA was measured using ELISA in patients with SLE (374), RA (354), Mixed connective tissue disease (MCTD, 77), Systemic sclerosis (SSc, 331), Sjögren's syndrome (SjS, 324), primary antiphospholipid syndrome (PAPs, 65), undifferentiated connective tissue disease (UCTD, 118) and 515 matched healthy controls (HC). Cardiovascular score (CV) was broadly defined based on clinical disease symptoms. Anti-PC and anti-MDA peptide/protein characterization were compared using a proteomics de novo sequencing approach. anti-MDA and anti-PC were extracted from total IgM. The proportion of Treg cells was determined by flow cytometry. The maximal difference between cases and controls was shown for MCTD: significantly lower IgM Anti-PC but not anti-MDA among patients (median 49.3RU/ml vs 70.4 in healthy controls, p(t-test) = 0.0037). IgM low levels were more prevalent in MCTD, SLE, SjS, SSc and UCTD. IgM anti-PC variable region profiles were different from and more homologous than anti-MDA. Anti-PC but not anti-MDA were significantly negatively correlated with CV in the whole patient group. In contrast to IgM anti-PC, anti-MDA did not promote polarization of Tregs. Taken together, Anti-PC is decreased in MCTD and also in SLE, SjS and SSc but not in other studied diseases. Anti-PC may thus differentiate between these. In contrast, anti-MDA did not show these differences between diseases studied. Anti-PC level is negatively correlated with CV in the patient group cohort. In contrast to anti-PC, anti-MDA did not promote Treg polarization. These findings could have both diagnostic and therapeutic implications, one possibility being active or passive immunization with PC in some rheumatic conditions.

Authors+Show Affiliations

Unit of Immunology and Chronic Disease, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.Unit of Immunology and Chronic Disease, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.Division of Physiological Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.Division of Physiological Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.Unit of Immunology and Chronic Disease, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.No affiliation info availableUnit of Immunology and Chronic Disease, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. GENYO, Center for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Government, Parque tecnolуgico de la salud, 18016, Granada, Spain.Unit of Immunology and Chronic Disease, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. johan.frostegard@ki.se.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32620913

Citation

Thiagarajan, Divya, et al. "IgM Antibodies Against Malondialdehyde and Phosphorylcholine in Different Systemic Rheumatic Diseases." Scientific Reports, vol. 10, no. 1, 2020, p. 11010.
Thiagarajan D, Oparina N, Lundström S, et al. IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases. Sci Rep. 2020;10(1):11010.
Thiagarajan, D., Oparina, N., Lundström, S., Zubarev, R., Sun, J., Alarcon-Riquelme, M., & Frostegård, J. (2020). IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases. Scientific Reports, 10(1), 11010. https://doi.org/10.1038/s41598-020-66981-z
Thiagarajan D, et al. IgM Antibodies Against Malondialdehyde and Phosphorylcholine in Different Systemic Rheumatic Diseases. Sci Rep. 2020 Jul 3;10(1):11010. PubMed PMID: 32620913.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases. AU - Thiagarajan,Divya, AU - Oparina,Nina, AU - Lundström,Susanna, AU - Zubarev,Roman, AU - Sun,Jitong, AU - ,, AU - Alarcon-Riquelme,Marta, AU - Frostegård,Johan, Y1 - 2020/07/03/ PY - 2020/01/09/received PY - 2020/05/24/accepted PY - 2020/7/5/entrez PY - 2020/7/6/pubmed PY - 2020/7/6/medline SP - 11010 EP - 11010 JF - Scientific reports JO - Sci Rep VL - 10 IS - 1 N2 - IgM antibodies against phosphorylcholine (anti-PC) and malondialdehyde (anti-MDA) may have protective properties in cardiovascular and rheumatic diseases. We here compare these antibodies in systemic rheumatic conditions and study their properties. Anti-PC and anti-MDA was measured using ELISA in patients with SLE (374), RA (354), Mixed connective tissue disease (MCTD, 77), Systemic sclerosis (SSc, 331), Sjögren's syndrome (SjS, 324), primary antiphospholipid syndrome (PAPs, 65), undifferentiated connective tissue disease (UCTD, 118) and 515 matched healthy controls (HC). Cardiovascular score (CV) was broadly defined based on clinical disease symptoms. Anti-PC and anti-MDA peptide/protein characterization were compared using a proteomics de novo sequencing approach. anti-MDA and anti-PC were extracted from total IgM. The proportion of Treg cells was determined by flow cytometry. The maximal difference between cases and controls was shown for MCTD: significantly lower IgM Anti-PC but not anti-MDA among patients (median 49.3RU/ml vs 70.4 in healthy controls, p(t-test) = 0.0037). IgM low levels were more prevalent in MCTD, SLE, SjS, SSc and UCTD. IgM anti-PC variable region profiles were different from and more homologous than anti-MDA. Anti-PC but not anti-MDA were significantly negatively correlated with CV in the whole patient group. In contrast to IgM anti-PC, anti-MDA did not promote polarization of Tregs. Taken together, Anti-PC is decreased in MCTD and also in SLE, SjS and SSc but not in other studied diseases. Anti-PC may thus differentiate between these. In contrast, anti-MDA did not show these differences between diseases studied. Anti-PC level is negatively correlated with CV in the patient group cohort. In contrast to anti-PC, anti-MDA did not promote Treg polarization. These findings could have both diagnostic and therapeutic implications, one possibility being active or passive immunization with PC in some rheumatic conditions. SN - 2045-2322 UR - https://www.unboundmedicine.com/medline/citation/32620913/IgM_antibodies_against_malondialdehyde_and_phosphorylcholine_in_different_systemic_rheumatic_diseases L2 - http://dx.doi.org/10.1038/s41598-020-66981-z DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.